Pure Biologics

Antibodies & aptamers · Myasthenia gravis, oncology

Overview

Dual antibody + aptamer discovery platforms (PureSelect / PureApta). Lead apheresis program PB003 for myasthenia gravis; pipeline refocused on lead assets.

What they do

Pure Biologics is a Wrocław-based, Warsaw Stock Exchange-listed biopharmaceutical company researching biological drugs and non-systemic therapies in immuno-oncology, autoimmunity and rare diseases. It is distinctive for running two complementary discovery engines: PureSelect (in-vitro antibody discovery via phage display) and PureApta (aptamer discovery for therapeutic and diagnostic molecules).

Lead program & status

Its lead program, PB003 (Deep Apheresis), is a non-systemic extracorporeal approach aimed at myasthenia gravis and related autoimmune neurological disorders, designed to remove disease-driving pathogenic factors from a patient's blood. Pure Biologics also runs related autoimmune-apheresis work such as the AptaMG (PB005) project, which uses PureApta-selected aptamers to improve plasmapheresis in myasthenic crisis. As of 2024 the company had refocused its pipeline on its lead assets to manage cash, including adjusting timelines on the PB003 CMC package pending earlier-stage results. Earlier oncology antibody programs informed the platforms but the strategic emphasis has shifted toward the apheresis-based lead.

Why it matters

Combining antibody and aptamer discovery under one roof is unusual, and a non-systemic apheresis therapy for myasthenia gravis could offer a differentiated, potentially safer alternative to systemic immunosuppression for a serious rare disease.

FAQ

What are PureSelect and PureApta?

They are Pure Biologics' two discovery platforms: PureSelect generates antibodies in vitro using phage display, while PureApta discovers aptamers with therapeutic and diagnostic potential.

What is PB003?

PB003 (Deep Apheresis) is Pure Biologics' lead program, a non-systemic extracorporeal therapy aimed at myasthenia gravis and related autoimmune neurological disorders.

Has Pure Biologics changed its strategy?

As of 2024 the company refocused its pipeline on its lead assets and adjusted some program timelines to manage resources, prioritizing its apheresis programs.

Company website / source ↗ Open the interactive map →